Next Article in Journal
Combined Radiofrequency Ablation and Left Atrial Appendage Closure in Atrial Fibrillation and Systolic Heart Failure
Previous Article in Journal
Diagnostic Approach to Pulmonary B-Cell Lymphomas in Small Biopsies, with Practical Recommendations to Avoid Misinterpretation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 13
Issue 21
10.3390/diagnostics13213324
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Oral Pathogenic Bacteria and the Oral–Gut–Liver Axis: A New Understanding of Chronic Liver Diseases

by
Yumeng Lei
†,
Simin Li
†,
Mingxin He
,
Zichun Ao
,
Jiadun Wang
,
Qingming Wu
and
Qiang Wang
*
Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Institute of Infection, Immunology and Tumor Microenvironment, School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Diagnostics 2023, 13(21), 3324; https://doi.org/10.3390/diagnostics13213324
Submission received: 12 September 2023 / Revised: 20 October 2023 / Accepted: 24 October 2023 / Published: 26 October 2023
(This article belongs to the Section Pathology and Molecular Diagnostics)
Browse Figure
Versions Notes

Abstract

:
Liver diseases have long been a prevalent cause of morbidity and mortality, and their development and progression involve multiple vital organs throughout the body. Recent studies on the oral–gut–liver axis have revealed that the oral microbiota is associated with the pathophysiology of chronic liver diseases. Since interventions aimed at regulating oral biological disorders may delay the progress of liver disease, it is crucial to better comprehend this process. Oral bacteria with potential pathogenicity have been extensively studied and are closely related to several types of chronic liver diseases. Therefore, this review will systemically describe the emerging role of oral pathogenic bacteria in common liver diseases, including alcoholic liver disease (ALD), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), cirrhosis, autoimmune liver diseases (AILD), and liver cancer, and bring in new perspectives for future research.

1. Introduction

Despite the great efforts made in the last decade to fight liver disease, it still has a major impact on global health. A recent report updated the global burden of liver disease: 2 million deaths worldwide (1 in 25 deaths globally), one in three female liver deaths, the 11th leading cause of death globally, and the 15th leading cause of disability-associated life years [1]. In 2016, liver disease-related expenditures in the United States were USD 32.5 billion, with healthcare expenditures increasing 4% annually for more than 20 years [2]. It is estimated that more than one-fifth of the Chinese population is affected by some form of chronic liver disease (CLD), particularly cirrhosis, hepatocellular carcinoma (HCC), NAFLD, and ALD. CLD and its complications are responsible for significant morbidity and mortality worldwide [3].
The gut microbiota and numerous liver disorders are closely related [4]. Recent evidence suggests a potential link between oral microbial dysbiosis and the occurrence and development of liver disorders; however, the precise influencing mechanism is still unclear [5]. Therefore, in order to develop more effective strategies for preventing and treating liver diseases, it is crucial to comprehend the invasion route of oral pathogenic bacteria as well as any potential biological aspects. The intestine and the oral cavity are part of the same gastrointestinal tract and are related anatomically. There is increasing evidence that oral microbiota can reach the gastrointestinal tract through the bloodstream or intestinal route [6]. The transfer of oral microbiota to the intestinal tract has the potential to aggravate various intestinal conditions and, more importantly, may contribute to the development of liver disease by affecting the intestinal microbiota [7]. This review article aims to highlight the role of oral pathogenic bacteria such as Porphyromonas gingivalis (P. gingivalis), P. intermedia, and S. pyogenes in various liver diseases and to explore the oral–gut–liver axis as a new perspective and direction for future research.

2. Oral Microecology

According to information from the Human Oral Microbiome Database (HOMD), there are 774 species of oral bacteria in the oral cavity. The homeostasis of the oral microbiota is of great importance for oral diseases and systemic diseases, especially liver diseases. Dental caries (tooth decay), periodontitis, gingivitis, and pulp abscesses are only a few of the oral illnesses that can arise from dysbiosis of the oral microbiota [8].
Periodontitis is a chronic inflammatory disease caused by bacteria in the oral cavity. As inflammation persists, periodontal tissues such as gums, periodontal ligaments, cementum, and alveolar bone are destroyed. The periodontal bacteria detected in the subgingival pocket of patients with periodontitis and related to the occurrence and development of periodontitis include P. gingivalis, Tannerella, Treponema pulposus, Proctella intermedia, and Actinobacteria [9].
P. gingivalis is present in healthy populations and is recognized as a host-adapted pathogen that can cause pathogenicity only when the ecological balance between host and bacteria is disrupted. Also, the bacterium may be involved in regulating the development of plaque biofilms, coordinating and controlling their pathophysiological mechanisms to minimize damage to the host. In particular, during the inflammatory process of chronic periodontitis, P. gingivalis has the ability to evade the host’s immune response and obtain access to nutrients in the microenvironment, and its survival and proliferation are directly related to the development of periodontitis [10].
In recent years, the primary virulence factors utilized by P. gingivalis have been identified and characterized, including a mixture of toxins, mainly proteases known as gingival proteases, which promote the invasion of gingival tissues [11]. The main virulence factor of P. intermedia 17 (Pi17) is mainly the extracellular mucopolysaccharide (EPS) [12]. A. actinomycetemcomitans is a Gram-negative pathogenic anaerobic bacterium that causes periodontal diseases such as limited invasive periodontitis (LAP) and periodontitis. Leukotoxins, lipopolysaccharides (LPSs), surface-associated substances, and enzymes are the principal pathogenic factors of common actinomycetes [13]. In addition, S. mutans is a major caries-causing bacterium with a variety of caries-related characteristics, including EPS synthesis, biofilm formation, acid production, and acidity [14], which is also proposed to be a cause of non-alcoholic fatty liver disease [15]. P. intermedia readily colonizes healthy dental biofilms and has been associated with periodontal disease [16]. The names of certain oral pathogenic species and their properties are listed in Table 1.
When the oral microecology is disturbed, various pathogenic bacteria, as previously mentioned, will produce virulence factors, which can cause diseases not only in the mouth but also in other areas of the body, such as the intestine and liver [17]. Apart from oral health issues, a large amount of evidence indicates that oral bacteria are closely related to systemic diseases as well, including, but not limited to, inflammatory bowel diseases (IBD) [18], diabetes [19], brain health [20], liver diseases [21], and other conditions. Furthermore, the oral microbiota has also been associated with various kinds of cancer development [8]. Nevertheless, there is a bi-directional relationship, and the oral microbiome is simultaneously modified by systemic diseases [22,23]. Collectively, the oral microbial ecosystem is of great significance to human well-being.

3. Oral–Gut–Liver Axis

The oral cavity and the gut are the two major microbial reservoirs in the human body [24]. However, some differences exist in the distribution of the oral and intestinal microbiota because of the presence of the oral–intestinal barrier [25]. However, there are certain differences in the distribution of oral and intestinal microbiota because of the existence of the oral–intestinal barrier [26]. On the other hand, in the case of oral–gut barrier dysfunction, oral microbiota can be transferred to the intestinal mucosa more easily [27]. For instance, studies have revealed that typical pathogenic bacteria in the mouth (F. nucleatucm and P. gingivalis) can be found in the colon of periodontitis patients [28]. There is also increasing evidence linking the oral microbiota to the occurrence and development of gastrointestinal cancer [29]. Therefore, scholars proposed the view of the “oral–gut–axis”. Ectopic colonization of oral microbiota, such as P. gingivalis, S. mutans, and F. nucleatum, may lead to the destruction of the intestinal epithelial barrier, excessive secretion of inflammatory factors, destruction of the host immune system, and imbalance of the intestinal microbiota, thus aggravating chronic intestinal inflammation and then triggering or aggravating intestinal diseases [30].
Marshall first put forward the concept of the “gut–liver axis” in 1998 [31]. The gut-liver axis consists of two-way interaction/communication pathways between the gastrointestinal tract and the liver. Intestinal-derived products can be transported to the liver via the biliary tract, portal vein, and systemic circulation, affecting various liver functions. Moreover, intestinal-derived products can also be transported to the intestines via hepatic feedback pathways, controlling intestinal metabolic functions and affecting the integrity of the intestinal barrier and the composition of the microbiota [32]. On the one hand, the liver can directly affect the reproduction of the intestinal gut microbiota by secreting bile acid, regulating the absorption of intestinal substances and the proliferation of colon cells, and affecting the intestinal mucosal barrier function and intestinal environment [33]. On the other hand, the increase in intestinal microbial transfer to the liver may lead to more severe liver damage [34]. Intestinal microbiome imbalance will lead to increased levels of LPSs in the gut, the liver translocation of LPSs under the action of portal vein circulation, and the high expression of Toll-like receptor 4 (TLR-4) in the liver, while TLR4 mediated TGF-β. The signal will result in liver inflammation, fibrosis, and HCC if it is continuously activated [35].
With the introduction of the “oraltgut axis” and “guttliver axis”, people gradually discovered that the oral microbiota can communicate with the liver through the gastrointestinal tract, blood, and portal circulation. Oral bacteria and their metabolites, after arriving at the gut and being absorbed there, are directly transmitted to the liver through the portal vein or employed as energy or as signal and regulatory molecules to participate in liver metabolism [36]. According to an in vitro study, swallowing periodontal pathogenic bacteria can exacerbate NAFLD, possibly by inducing intestinal ecological dysregulation and a subsequent influx of intestinal bacteria and/or bacterial products leading to dysregulated gene expression [37]. The diagram of the oral–gut–liver axis is shown in Figure 1.
The liver is the organ in closest contact with the gut, where the oral microbiota is prevalent, and is exposed to a high variety of bacterial components and metabolites [38]. There has been evidence of possible crosstalk between the oral microbiota, gut microbiota, and liver function in liver disease. Studies in both human and animal models have indicated that colonic inflammation increases intestinal permeability in patients with liver disease, leading to the translocation of bacteria and bacterial products to the liver, in which case bacteria from the oral cavity or their by-products have the potential to disseminate to the liver, thereby contributing to the pathogenesis of liver disease [39,40,41]. Significant changes in the gut microbiota of cirrhotic patients may be related to the invasion of the gut by oral bacterial species, and genetic tracing has shown that most of them are of oral origin [42]. The altered collateral phenomena made possible by the reduced bile and gastric acid secretion present in cirrhosis have also been theorized to render the intestinal tract more easily admissible or accessible to oral pathogens [43]. In summary, oral bacteria can be transferred to the gastrointestinal tract, where they contribute to inflammation and tumorigenesis, and oral bacteria colonizing the intestinal tract can further disseminate to the liver and cause liver lesions.

4. Liver Diseases and Oral Pathogenic Bacteria

Changes in the oral microbiota related to liver diseases are shown in Table 2.

4.1. Alcoholic Liver Disease and Oral Pathogenic Bacteria

Every year, ALD claims the lives of more than 3.3 million people worldwide [49]. Compared to non-Asian populations, some Asian populations have a higher risk of developing cirrhosis and cancer due to excessive alcohol consumption [50]. The disruption of the microbiota is an important risk factor for ALD, in addition to alcohol consumption. A significant increase in pathogenic bacteria and toxic metabolites in the oral cavity can transfer to the liver through the gastrointestinal tract or blood circulation, leading to liver damage [32].
A recent study has pointed out that there is a potential correlation between oral bacterial dysbiosis and ALD [45]. There is a general reduction in bacterial diversity in the microbiome of patients with all forms of ALD [51]. Fan et al. found that drinkers might own a varying oral bacteria community composition compared to non-drinkers, including increased colonization of potentially pathogenic bacteria [52]. More profoundly, Zhou et al. provide preliminary data, supporting the notion that P. gingivalis may be related to ALD and function as a novel risk factor in both the onset and severity of acute alcoholic hepatitis (AAH) [53]. An elevated antibody response to P. gingivalis was observed in AAH in this study. Plasma anti-P. gingivalis IgM, IgG, and IgA were significantly elevated in patients with severe AAH, revealing that P. gingivalis may be a novel risk factor for the progression and severity of AAH. Consequently, targeting oral pathogens seems to provide an underlying approach to the prevention and treatment of ALD [54].

4.2. Non-Alcoholic Fatty Liver Disease and Oral Pathogenic Bacteria

To date, there have been a number of exciting findings regarding the oral microbiota and its role in NAFLD progression [47,55]. Periodontitis can worsen a simple fatty liver into a fibrotic disease through the production of fibrosis mediators such as transforming growth factor-β1 (TGF-β1) and galectin-3 [56]. The incidence of oral pathogenic bacteria was compared between patients with NAFLD and control subjects, and it was found that patients with NAFLD had a significantly higher detection rate of P. gingivalis infection [57]. In addition, the tooth infection caused by P. gingivalis might worsen the development of a NASH liver from a simple fat liver to a fat liver and make it worse and worse [44]. However, the elimination of P. gingivalis can inhibit liver fibrosis and inflammation in NASH [58].
On the one hand, the colonization of P. gingivalis in the liver found in pathological sections may be an important cause of liver injury. Atsuhiro et al. demonstrated that odontogenic infection with P. gingivalis exacerbates fibrosis in NASH via hepatic stellate cell activation [47]. P. gingivalis induces apoptosis by upregulating phosphor-smad2 (TGF-β 1’s key signaling molecule) and immunoexpression of galectin-3, which enables macrophage accumulation and a dramatic increase in the number of hepatic crown structures associated with liver fibrosis, as well as the area of fibrosis. Yao et al. showed that P. gingivalis may also induce the development of a nonalcoholic fatty liver through iron death [59]. On the other hand, one possible mechanism is that the bacteria P. gingivalis can transport protease to the liver through the outer membrane vesicles and then affect the liver cells. For example, Mariko et al. showed that the outer membrane vesicles (OMVs) of P. gingivalis could attenuate insulin-induced Akt/glycogen synthase kinase-3 β signaling in a vinculin-dependent manner in HepG2 cells [60].
Currently, targeted drug therapy for NAFLD is limited, and liver transplantation is considered the optimal treatment [61]. However, the prognosis after liver transplantation is poor in terms of survival and high tumor recurrence rates, and the development of novel therapies is urgently needed. Bajaj et al. found that periodontal treatment was associated with the improvement of oral microbial dysbiosis and systemic inflammation by assessing endotoxemia and inflammation perception [62]. Notably, there seems to be an association between periodontitis and serum ALT levels. In a Japanese study, it was found that men with high serum ALT levels were more likely to develop periodontitis than those with low serum ALT levels [57]. Yoneda et al. performed periodontal treatment, including oral scaling and root planing, topical administration of minocycline hydrochloride, and hygiene instruction, in patients with NAFLD suffering from periodontitis [57]. The results showed that AST and ALT levels decreased 1 month after baseline, and the decline reached statistical significance after 2 months; after 3 months, a further decrease was observed [57]. These advances have enriched our understanding of the mechanisms of the “oral–gut–liver axis” and have confirmed the positive effects of periodontal therapy on the management of liver disease.

4.3. Cirrhosis and Oral Pathogenic Bacteria

Quantitative metagenomics revealed that most gut-enriched, taxonomically assigned species in cirrhotic patients originated from the oral cavity and differed significantly at the gene and functional levels [42]. A cohort study by Fernando et al. observed an important risk association between cirrhosis and periodontitis, with a higher prevalence of periodontitis in patients with cirrhosis compared to healthy controls [63]. Lea et al. achieved similar results, demonstrating a substantial correlation between periodontitis and mortality, complications, and nutritional risk scores in patients with cirrhosis [64]. Therefore, some scholars believe that periodontitis is a risk factor for infection in patients with liver cirrhosis, and periodontal treatment for patients with liver cirrhosis may have a mitigating effect [65].
Anders et al. used long-read Illumina sequencing to analyze the subgingival microbiome of 21 patients with periodontitis and liver cirrhosis [48]. The subgingival microbiota is mainly composed of bacteria belonging to the Firmicutes phylum, with Actinomycetes and Bacteroidetes phyla in a smaller range [48]. It is well known that patients with periodontitis have high serum levels of antibodies to P. gingivalis. There have been clinical reports of a morbidly obese patient with NASH-related cirrhosis who died of sepsis caused by a P. gingivalis infection [66]. This case may represent an important implication of P. gingivalis in the progression of cirrhosis in patients with NASH.
It has been proven that systemic periodontal therapy in patients with liver cirrhosis can improve endotoxemia, systemic and local inflammation, and the abnormal microbial metabolism in saliva and feces within 30 days. However, in the cirrhosis group without periodontal treatment, endotoxin and LPS-binding protein were increased for identical durations [62]. Therefore, periodontal therapy may be a potential adjunctive therapy to prolong survival in patients with cirrhosis.

4.4. Hepatocellular Carcinoma and Oral Pathogenic Bacteria

Hepatocellular cancer (HCC) is about the sixth most common cancer form, accounting for approximately 9.2% of all cancer-related mortality [27]. Most patients with HCC have developed chronic liver disease, which is caused by NAFLD and alcohol-related fatty liver disease.
Comprehensive analysis of the microbiome and host transcriptome has illustrated the association between the gut microbiota and clinical outcomes in HBV-associated HCC. The change in oral microorganisms may also accelerate the occurrence of HCC. Brende et al. provided evidence that the oral microbiome of HCC cases showed significantly lower alpha diversity and significant differences in the relative abundance of 30 taxa compared to healthy controls, with Cyanobacteria being enriched in HCC [67]. Microcystins produced by cyanobacteria are the most widely distributed hepatotoxins and are strong promoters of liver tumors. Therefore, oral Cyanobacteria may, directly and indirectly, promote liver tumors through microcystins and other hepatotoxins, serving as an independent risk factor for HCC. Li et al. detected the diversity of oral bacteria in patients with different liver diseases and healthy controls by 16SrDNA high-throughput sequencing and bioinformatics analysis [31]. It was discovered that P. gingivalis, Epsilon proteobacteria, Actinobacteria, Clostridia, and Fusobacteria had a higher abundance in patients with HCC, and with the development of liver diseases, the species of saliva bacteria decreased. This might provide useful information and possible biological symbols for patients with liver disease. Furthermore, an epidemiological study has shown a positive association between periodontal diseases and cancers (including HCC) [68]. Yang et al. examined the association between tooth loss and the incidence of primary HCC in a prospective cohort of Finnish male smokers and found that more tooth loss was associated with a higher risk of primary HCC [69].
Robert et al. revealed the mechanism of the intestinal hepatic axis promoting the development of HCC, including biological disorders, intestinal leakage, and bacterial metabolites [70]. LPSs released by periodontal bacteria combine with TLR-4 and TLR-2 to stimulate T lymphocytes and macrophages to produce cytokines and proinflammatory mediators [71]. The production of these factors may induce an increase in NADPH oxidase 4 (NOX-4) and malondialdehyde levels in the liver and a decrease in glutathione, catalase, and selenium levels, which would lead to the decline of liver function, continuous inflammation of the liver, and the accelerated occurrence of HCC. Furthermore, as the first pathogenic bacteria of periodontitis, P. gingivalis can change the fatty acid profile in the tongue tissue and serum of mice, thereby promoting the development of cancer [72]. Interestingly, studies have shown that HGFs are involved in the development of oral cancer, which indirectly demonstrates a significant association between oral disease and liver disease [73]. The human microbiome is valuable for the diagnosis of HCC and provides a new strategy for the targeted treatment of HCC [74]. Oral microbiology has great potential for clinical application and may be widely used in the future for the diagnosis, treatment, and prognosis of liver diseases and cancers, bringing additional benefits to the HCC population, and the removal of periodontal pathogens may be a new direction in the diagnosis and treatment of HCC.

4.5. Autoimmune Liver Disease and Oral Pathogenic Bacteria

The oral microbiome is a key regulator of immunity based on the association between dysregulated oral microecology and autoimmune disease, loss of immune tolerance to autoantigens, and increased inflammatory events [75]. Epidemiological evidence has suggested that bacterial infection is associated with primary biliary cholangitis (PBC), and bacterial infection is considered to be one of the most important environmental factors contributing to the disruption of mitochondrial autoantigen tolerance in PBC [76]. A series of studies also revealed that disruption of tolerance to mitochondrial autoantigens through E. coli infection may result in auto-reactive T lymphocytes and B lymphocytes recognizing autoantigens [77]. E. coli is not the only candidate for breaking tolerance to mitochondrial autoantigens; other bacteria, such as Novosphingobium aromaticivorans and Lactobacillus delbrueckii, may be involved in the etiology of PBC through molecular mimicry [76].
Although the initiating factors of autoimmune hepatitis (AIH) etiology are unknown, the role of the oral–gut–liver axis in the pathogenesis of AIH has attracted attention. Rao et al. collected 204 saliva samples (from 68 AIH patients and 136 healthy controls) and performed microbial sequencing and found increased oral microbial diversity in the AIH and differences with the overall oral microbial composition of healthy controls both at the phylum and genus levels [78]. Another study evaluated the correlation between immune biomarkers measured by Bio-Rad and the oral microbiome of patients with PBC and AIH, both of which differed from healthy controls in oral microbiota composition and abundance [46]. Immunologic biomarker analysis revealed elevated levels of inflammatory cytokines and immunoglobulin A in the saliva of patients with autoimmune liver diseases (AILD) and a positive correlation between the relative abundance of Veillonella and the levels of IL-1β, IL-8, and immunoglobulin A in saliva, as well as the relative abundance of Lactobacillales in stool. In addition, Rao et al. established that several gene functions of the AIH group were proven to be advantageous, including membrane transport, transporter, and flagellum assembly. The main virulence factors of certain oral pathogenic bacteria, such as P. gingivalis and F. nucleatum, are known to be proteases, bacterial hairs, iron uptake transport proteins, and toxic outer membrane vesicles, leading to a local inflammatory response [79].
These findings suggest that the oral microbiota and associated inflammatory factors may serve as potential biomarkers to aid in the diagnosis of the onset and progression of AIH, but the specific mechanisms of the modulatory effects of the oral microbiota on AIH remain to be further elucidated.

5. Prevention and Management

5.1. Oral Hygiene

Patients who receive good oral care through improved hygiene practices experience a shift in the composition of their oral microbiota toward a healthy state, with a reduction in the total number of bacteria in saliva and plaque and a reduction in the proportion of periodontal pathogens. Since the microbial load in the oral cavity correlates with the severity of periodontal disease, oral hygiene is crucial for controlling the bacterial load in the oral cavity to help avoid inflammation and bacteremia, consequently maintaining oral health and lowering the risk of liver disease [80,81]. Oral hygiene measures proven to be beneficial include brushing with fluoride toothpaste and antibacterial mouthwash to reduce plaque, which can be effective in relieving gum inflammation [82,83]. There may be a negative correlation between the frequency of brushing and the prevalence of NAFLD, as reported in a cross-sectional study [84]. Several intervention studies have demonstrated that oral hygiene instruction and scaling/root planing (SRP) significantly improve AST and ALT levels, endotoxin levels, and liver fat content (LFC) in patients with liver disease, with a concomitant significant reduction in Porphyromonas gingivalis immunoglobulin G (IgG) antibody titers [56,57,85].
The aforementioned studies support the potential impact of oral hygiene on improving liver function and also reinforce the causal relationship between periodontal disease and NAFLD. However, more evidence is needed in the future to clarify the effectiveness of oral hygiene care in the treatment of liver disease.

5.2. Antimicrobial Peptides

Antimicrobial peptides are important contributors to maintaining balance in the oral environment and regulating oral biofilm microecological dysregulation through broad-spectrum antimicrobial activity. Through broad-spectrum antimicrobial activity, they can kill pathogenic microorganisms, promote tissue healing, and play a significant role in several oral diseases (e.g., caries, periodontal disease, mucosal disease, etc.) [86]. Epithelial cells produce salivary antimicrobial peptides, such as β-defensins, α-defensins, and LL-37, which not only act as bactericidal substances, but also as alarm signals when pathogens invade [87]. Notably, LL-37 has antifungal, antibacterial, and anti-biofilm properties, conditioning symbiotic actinomycetes, inhibiting the formation of biofilm by this bacterium, and preventing the growth of F. nucleatum [88]. The effect of LL-37 on Gram-negative bacteria may be particularly important, especially some harmful bacteria associated with rapidly progressive periodontal disease [89].
Several findings have highlighted the pathophysiological role of antimicrobial peptides in the progression of liver disease: Antimicrobial peptides inhibit intestinal inflammation-promoted LPS metastasis, liver inflammation, and fibrogenesis in NASH [90]; Cathelicidin-related antimicrobial peptides (CRAMP) modulate inflammatory vesicle activation by reducing LPS binding and UA production, thereby alleviating alcoholic liver disease [69]; In a mouse model of alcoholic hepatitis (AH), 1Z1 treatment upregulated the expression of the antimicrobial peptides Reg3b and Reg3g in the intestinal epithelium, reducing and increasing the number of Bacteroides and Lactobacillus, respectively, to regulate the microbiome and prevent intestinal barrier disruption and bacterial translocation, thereby inhibiting ethanol-induced liver injury, steatosis, and inflammation [91]. LL-37 has positive effects on different liver diseases: it is involved in regulating cell proliferation and the production of pro-inflammatory cytokines in hepatocellular carcinoma cells, and it also reduces hepatitis C virus infection [92]. Therefore, moderate supplementation with antimicrobial peptides may have a positive effect on regulating the oral microbiota and thus alleviating liver disease.

5.3. Prebiotics and Probiotics

Scientific evidence for probiotics and prebiotics confirms that they are microbiota management tools that improve host health [93]. In recent years, prebiotics and probiotics have been applied to the oral microbiome [94]. Administration of some probiotics and prebiotics can alleviate metabolic liver diseases such as NAFLD and NASH, which may progress to cirrhosis and hepatocellular carcinoma [95]. Prebiotic intervention reduces liver weight and steatosis, as well as hepatic adipogenic gene expression, hepatic inflammation, endotoxemia, and hepatic TLR4 signaling [96]. Probiotics manage periodontal disease by assisting in reducing oral damage from harmful bacteria, regulating local and systemic immune responses, and reducing plaque and gum inflammation [97]. Research data showed that Lactobacillus has antibacterial activity against oral pathogenic bacteria such as S. mutans, P. gingivalis, P. intermedia, and A. actinomycetemcomitans. The positive effect of probiotics and prebiotics on various liver diseases (hepatic encephalopathy, cirrhosis, and NAFLD) has been demonstrated [98]. Administration of Bifidobacterium and Lactobacillus has been shown to improve liver transaminase levels and histological lesions [99]. In conclusion, prebiotics and probiotics not only maintain oral health homeostasis by regulating the oral microbiota, but also serve as effective adjuvants to the conventional treatment of liver disease without side effects on the host.

6. Discussion

There is growing evidence that periodontitis is a risk element for the development of numerous systemic diseases, including liver disease. The interplay of immunological factors, genetic vulnerability, intestinal microorganisms, and environmental variables—of which compromised immune regulation plays a crucial role—determines the etiology and pathophysiology of liver illnesses. The incidence rate of periodontitis, the depth of the periodontal pocket, and the rate of tooth loss in patients with liver disease are significantly higher than in healthy controls, which are closely linked to changes in the oral microbiota [100]. In addition, periodontitis-related oral bacteria might transfer to the gut and, along with the intestinal microbiota, contribute to the barrier dysfunction of intestinal epithelial cells, thus aggravating liver damage.
To elucidate the role of oral pathogenic bacteria in diseases, we summarized several mechanisms of their remote transmission and liver damage. Due to the interconnectivity between the oral cavity and the intestine, a large number of oral bacteria can continuously enter the intestine through saliva, causing disruption of the intestinal microbiota, increasing intestinal epithelial permeability, or causing endotoxemia [101]. In addition, oral pathogens, such as P. gingivalis, can output a variety of virulence factors [60] and reduce innate immunity and adaptive immunity, which enables pathogens to survive and reproduce in the host, thus destroying periodontal tissue and participating in the occurrence and development of systemic diseases [102]. The recombination of antimicrobial peptides and the destruction of phagocyte function contribute to the escape of P. gingivalis.
Biomedical research in the past decades has produced a large amount of evidence proving that P. gingivalis has contributed to the development of various liver diseases [103]. In this review, we summarized the existing evidence of the association between P. gingivalis as a risk regulator and different liver diseases from the perspective of epidemiological and biological research experiments. According to recent research results, we believe that P. gingivalis may be a key susceptibility factor in the microenvironment, which guides the development or poor prognosis of different liver diseases and cancers [55,104]. Several studies have reported the relationship between specific antibodies to P. gingivalis in serum and liver diseases [105]. In saliva specimens from patients with cirrhosis or previous rounds of hepatocellular carcinoma treatment, 50% contained FimA protein from P. gingivalis. The formation of purulent liver abscess (PLA) has three main routes of infection: hepatic artery, biliary tract, and portal vein; nevertheless, 50% are of implicit origin (source unknown). A case report showed that periodontal infection was a latent cause of PLA formation. Gingival bacilli and other periodontal pathogens isolated from the PLA, heart, kidney, and thrombus of the patient were detected by immunohistochemical staining [106]. Studies have shown that LPSs derived from P. gingivalis can cause excessive accumulation of liver lipids by activating NF-κB and JNK signaling pathways, thus leading to the occurrence and development of liver diseases [102]. These indicate that P. gingivalis may be one of the causes or inducers of liver disease.
Oral infection can activate the host immune system and trigger an inflammatory reaction [107]. When exogenous pathogens enter the oral cavity, they induce the body’s immune system to generate an immune response. If the intrinsic immune response fails to completely remove the pathogen, a subsequent specific adaptive immune response will be triggered to completely remove the pathogen, protect the organism, and form an immune memory that will lead to a faster and stronger immune response when the same pathogen is encountered the next time [108]. If the adaptive immune response also fails to completely clear the invading pathogens, a chronic infectious state will result. Long-term oral infection may lead to continuous activation of the immune system and increase the risk of systemic inflammation. Some possible mechanisms related to liver disease and periodontitis are dysbacteriosis, changes in the level of inflammatory agents, and oxidative stress [109]. The liver of rats with periapical periodontitis, compared with the control group, had higher levels of vitamin C, Na+/K+ATPase, and catalase activity, which indicated that there were oxidative stress reactions and hepatocyte degeneration induced by periapical periodontitis in the liver tissue [110]. In addition, bacteria and their metabolites enter the liver through the portal vein and can interact with the inherent sensors (TLR and NLR) of liver cells and Kupffer cells, resulting in the production of inflammatory mediators and thus causing liver damage.
Modulating gut microbial homeostasis and targeting oral pathogenic bacteria are currently the main therapeutic strategies for liver diseases based on the oral–gut–liver axis. Various therapeutic approaches targeting the microbiota have been developed: antibiotics, probiotics, prebiotics, synthetic probiotics, and fecal microbial transplants, all of which have been recognized as effective treatments for liver and metabolic diseases associated with gut microbiota dysbiosis [111,112]. Dietary fiber has been shown to improve early NAFLD by reducing calorie absorption and correcting imbalances in the gut microbiota [113]. Lactococcus lactis treatment modulates the formation, composition, and survival of oral bacterial biofilms, has potent antimicrobial and anti-inflammatory properties, and is also benefical in decreasing LFC, suggesting its promising efficiency in the treatment of NAFLD [114,115].
Also, oral inflammation treatment is one of the important complementary therapies for liver diseases. Kamata et al. conducted a multicenter randomized controlled trial to evaluate the effects of periodontal therapy on patients with NAFLD and discovered that periodontal therapy significantly reduced liver enzyme levels, endotoxin levels, and LFC in patients with NAFLD combined with periodontal disease [85]. A proof-of-concept clinical trial has reported that cirrhotic patients treated with periodontal therapy exhibit improved inflammation and endotoxemia, suggesting that periodontal therapy modulates the gut microbiome in cirrhotic patients and that this alteration appears to provide beneficial effects [62]. More research linking variations in oral microbiota diversity to clinical outcomes and therapeutic responsiveness is expected, and specific oral pathogenic bacteria may serve as biomarkers for gastrointestinal and liver diseases.

7. Future Direction

Having a better understanding of the mechanisms of the oral–gut–liver association is an exciting new frontier of research. Microecological dysregulation associated with periodontitis appears to exacerbate hepatic pathology, but the mechanisms of ectopic colonization of oral microbiota in the gut have not been fully elucidated. Further research is required to determine whether oral microbiota can reach the liver via the hematogenous pathway or whether it is indirectly regulated mainly through the oral–gut–liver axis. In addition, periodontitis exhibits intestinal microecological dysregulation, which is similar to the presentation of chronic liver disease [5]. It is still unexplored whether this microecological dysregulation is causally linked to one disease or whether the dysregulation shared by both diseases causes an inflammatory response.
Further prospective studies and sequencing of the entire macrogenomes of the oral and gut microbiomes may be needed in the future to gain a deeper understanding of the taxonomic and functional profiles of the oral and intestinal microbiota. Given the ease of sampling, coupled with the depth of information that can be retrieved from the oral microbiome, such studies may mark a significant shift in our approach to elucidating the role of the microbiome in liver disease [116]. As a result, there will be a greater chance of employing the oral pathogenic bacteria as biomarkers for extra-oral diseases, notably liver diseases, pointing the way to research into the unique functions and mechanisms of the oral–gut–liver axis [7].

8. Conclusions

In summary, changes in the abundance of oral pathogenic bacteria may influence the pathogenesis of various chronic liver diseases through the oral–gut–liver axis. Although there is no clinical approach for completely eradicating chronic liver disease, gut microbiota modulation as well as targeting oral pathogenic bacteria are currently the main therapeutic strategies for liver disease based on the oral–gut–liver axis. Some specific oral pathogens may be potential biomarkers for chronic liver disease and have innovative applications in screening, treatment, and prognosis for liver management. This may shed some light on future liver therapeutic strategies; integrating dentistry and clinical medicine will bring important clinical value. Further studies are required to determine the effectiveness and feasibility of the oral–gut–liver axis-based approach discussed in this review in the management of chronic liver disease and to elucidate the depth of the relationship between human physiology and the oral microbiome.

Author Contributions

Q.W. (Qiang Wang) organized the writing of this review. Y.L., S.L., M.H., Z.A., J.W., Q.W. (Qingming Wu) and Q.W. (Qiang Wang) divided the remaining task of writing. All authors have read and agreed to the published version of the manuscript.

Funding

The authors are cordially thankful to 2020 General Planning Fund Project for Humanities and Social Sciences of the Ministry of Education, China (Project No. 20YJA880053); The Scientific Research and Innovation Fund of Wuhan Asia General Hospital (Project No. 2022KYCX1-A04); Key research project of philosophy and social sciences of Hubei Provincial Department of Education in 2020 (Project No. 20D026) and Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Science and Technology (Project No. OHIC2022G05) for their financial support to conduct this project successfully.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

This thesis would not have been possible without the consistent and valuable references provided by our supervisor, whose insightful guidance and enthusiastic encouragement in shaping this thesis have gained our deepest gratitude.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Devarbhavi, H.; Asrani, S.K.; Arab, J.P.; Nartey, Y.A.; Pose, E.; Kamath, P.S. Global burden of liver disease: 2023 update. J. Hepatol. 2023, 79, 516–537. [Google Scholar] [CrossRef] [PubMed]
  2. Ma, C.; Qian, A.S.; Nguyen, N.H.; Stukalin, I.; Congly, S.E.; Shaheen, A.A.; Swain, M.G.; Teriaky, A.; Asrani, S.K.; Singh, S. Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis in the United States: 1996–2016. Am. J. Gastroenterol. 2021, 116, 2060–2067. [Google Scholar] [CrossRef] [PubMed]
  3. Verma, M.; Younossi, Z. Integrating Patient-Reported Outcomes within Routine Hepatology Care: A Prompt to Action. Hepatology 2021, 73, 1570–1580. [Google Scholar] [CrossRef] [PubMed]
  4. Jones, R.M.; Neish, A.S. Gut Microbiota in Intestinal and Liver Disease. Annu. Rev. Pathol. 2021, 16, 251–275. [Google Scholar] [CrossRef] [PubMed]
  5. Albuquerque-Souza, E.; Sahingur, S.E. Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis. Periodontol. 2000 2022, 89, 125–141. [Google Scholar] [CrossRef] [PubMed]
  6. Kitamoto, S.; Nagao-Kitamoto, H.; Hein, R.; Schmidt, T.M.; Kamada, N. The Bacterial Connection between the Oral Cavity and the Gut Diseases. J. Dent. Res. 2020, 99, 1021–1029. [Google Scholar] [CrossRef] [PubMed]
  7. Imai, J.; Kitamoto, S.; Kamada, N. The pathogenic oral-gut-liver axis: New understandings and clinical implications. Expert. Rev. Clin. Immunol. 2021, 17, 727–736. [Google Scholar] [CrossRef]
  8. Tuominen, H.; Rautava, J. Oral Microbiota and Cancer Development. Pathobiology 2021, 88, 116–126. [Google Scholar] [CrossRef]
  9. Usui, M.; Onizuka, S.; Sato, T.; Kokabu, S.; Ariyoshi, W.; Nakashima, K. Mechanism of alveolar bone destruction in periodontitis—Periodontal bacteria and inflammation. JPN Dent. Sci. Rev. 2021, 57, 201–208. [Google Scholar] [CrossRef]
  10. D’Ercole, S.; D’Addazio, G.; Di Lodovico, S.; Traini, T.; Di Giulio, M.; Sinjari, B. Porphyromonas Gingivalis Load is Balanced by 0.20% Chlorhexidine Gel. A Randomized, Double-Blind, Controlled, Microbiological and Immunohistochemical Human Study. J. Clin. Med. 2020, 9, 284. [Google Scholar] [CrossRef]
  11. Lunar Silva, I.; Cascales, E. Molecular Strategies Underlying Porphyromonas gingivalis Virulence. J. Mol. Biol. 2021, 433, 166836. [Google Scholar] [CrossRef]
  12. Kwack, K.H.; Jang, E.Y.; Yang, S.B.; Lee, J.H.; Moon, J.H. Genomic and phenotypic comparison of Prevotella intermedia strains possessing different virulence in vivo. Virulence 2022, 13, 1133–1145. [Google Scholar] [CrossRef] [PubMed]
  13. Gholizadeh, P.; Pormohammad, A.; Eslami, H.; Shokouhi, B.; Fakhrzadeh, V.; Kafil, H.S. Oral pathogenesis of Aggregatibacter actinomycetemcomitans. Microb. Pathog. 2017, 113, 303–311. [Google Scholar] [CrossRef] [PubMed]
  14. Lin, Y.; Gong, T.; Ma, Q.; Jing, M.; Zheng, T.; Yan, J.; Chen, J.; Pan, Y.; Sun, Q.; Zhou, X.; et al. Nicotinamide could reduce growth and cariogenic virulence of Streptococcus mutans. J. Oral. Microbiol. 2022, 14, 2056291. [Google Scholar] [CrossRef] [PubMed]
  15. Tonomura, S.; Naka, S.; Tabata, K.; Hara, T.; Mori, K.; Tanaka, S.; Sumida, Y.; Kanemasa, K.; Nomura, R.; Matsumoto-Nakano, M.; et al. Relationship between Streptococcus mutans expressing Cnm in the oral cavity and non-alcoholic steatohepatitis: A pilot study. BMJ Open Gastroenterol. 2019, 6, e000329. [Google Scholar] [CrossRef] [PubMed]
  16. Choi, E.Y.; Lee, J.E.; Lee, A.R.; Choi, I.S.; Kim, S.J. Nitrooleic acid inhibits macrophage activation induced by lipopolysaccharide from Prevotella intermedia. Nutr. Res. 2022, 106, 35–46. [Google Scholar] [CrossRef] [PubMed]
  17. Su, Y.; Ye, L.; Hu, C.; Zhang, Y.; Liu, J.; Shao, L. Periodontitis as a promoting factor of T2D: Current evidence and mechanisms. Int. J. Oral. Sci. 2023, 15, 25. [Google Scholar] [CrossRef] [PubMed]
  18. Read, E.; Curtis, M.A.; Neves, J.F. The role of oral bacteria in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 731–742. [Google Scholar] [CrossRef] [PubMed]
  19. Xiao, E.; Mattos, M.; Vieira, G.H.A.; Chen, S.; Corrêa, J.D.; Wu, Y.; Albiero, M.L.; Bittinger, K.; Graves, D.T. Diabetes Enhances, I.L-17 Expression and Alters the Oral Microbiome to Increase Its Pathogenicity. Cell Host Microbe 2017, 22, 120–128.e4. [Google Scholar] [CrossRef]
  20. Maitre, Y.; Micheneau, P.; Delpierre, A.; Mahalli, R.; Guerin, M.; Amador, G.; Denis, F. Did the Brain and Oral Microbiota Talk to Each Other? A Review of the Literature. J. Clin. Med. 2020, 9, 3876. [Google Scholar] [CrossRef]
  21. Abe, K.; Fujita, M.; Hayashi, M.; Okai, K.; Takahashi, A.; Ohira, H. Gut and oral microbiota in autoimmune liver disease. Fukushima J. Med. Sci. 2020, 65, 71–75. [Google Scholar] [CrossRef] [PubMed]
  22. Graves, D.T.; Corrêa, J.D.; Silva, T.A. The Oral Microbiota Is Modified by Systemic Diseases. J. Dent. Res. 2019, 98, 148–156. [Google Scholar] [CrossRef] [PubMed]
  23. Peng, X.; Cheng, L.; You, Y.; Tang, C.; Ren, B.; Li, Y.; Xu, X.; Zhou, X. Oral microbiota in human systematic diseases. Int. J. Oral. Sci. 2022, 14, 14. [Google Scholar] [CrossRef] [PubMed]
  24. Park, S.Y.; Hwang, B.O.; Lim, M.; Ok, S.H.; Lee, S.K.; Chun, K.S.; Park, K.K.; Hu, Y.; Chung, W.Y.; Song, N.Y. Oral-Gut Microbiome Axis in Gastrointestinal Disease and Cancer. Cancers 2021, 13, 2124. [Google Scholar]
  25. Wang, J.; Feng, J.; Zhu, Y.; Li, D.; Wang, J.; Chi, W. Diversity and Biogeography of Human Oral Saliva Microbial Communities Revealed by the Earth Microbiome Project. Front. Microbiol. 2022, 13, 931065. [Google Scholar] [CrossRef]
  26. Mo, S.; Ru, H.; Huang, M.; Cheng, L.; Mo, X.; Yan, L. Oral-Intestinal Microbiota in Colorectal Cancer: Inflammation and Immunosuppression. J. Inflamm. Res. 2022, 15, 747–759. [Google Scholar] [CrossRef] [PubMed]
  27. Zhao, L.; Zhang, X.; Zhou, Y.; Fu, K.; Lau, H.C.; Chun, T.W.; Cheung, A.H.; Coker, O.O.; Wei, H.; Wu, W.K.; et al. Effect of Entecavir on the Intestinal Microflor. Oncogene 2022, 41, 4200–4210. [Google Scholar] [CrossRef] [PubMed]
  28. Proc, P.; Szczepańska, J.; Zarzycka, B.; Szybka, M.; Borowiec, M.; Płoszaj, T.; Fendler, W.; Chrzanowski, J.; Zubowska, M.; Stolarska, M.; et al. Evaluation of Changes to the Oral Microbiome Based on 16S rR.NA Sequencing among Children Treated for Cancer. Cancers 2021, 14, 7. [Google Scholar] [CrossRef]
  29. Zhang, Y.; Niu, Q.; Fan, W.; Huang, F.; He, H. Oral microbiota and gastrointestinal cancer. Onco Targets Ther. 2019, 12, 4721–4728. [Google Scholar] [CrossRef]
  30. Qi, Y.; Wu, H.M.; Yang, Z.; Zhou, Y.F.; Jin, L.; Yang, M.F.; Wang, F.Y. New Insights into the Role of Oral Microbiota Dysbiosis in the Pathogenesis of Inflammatory Bowel Disease. Dig. Dis. Sci. 2022, 67, 42–55. [Google Scholar] [CrossRef]
  31. Lu, Y.X.; He, C.Z.; Wang, Y.X.; Ai, Z.S.; Liang, P.; Yang, C.Q. Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study. Infect. Dis. Ther. 2021, 10, 241–252. [Google Scholar] [CrossRef] [PubMed]
  32. Costa, C.F.F.A.; Sampaio-Maia, B.; Araujo, R.; Nascimento, D.S.; Ferreira-Gomes, J.; Pestana, M.; Azevedo, M.J.; Alencastre, I.S. Gut Microbiome and Organ Fibrosis. Nutrients 2022, 14, 352. [Google Scholar] [CrossRef] [PubMed]
  33. Rao, B.; Ren, T.; Wang, X.; Wang, H.; Zou, Y.; Sun, Y.; Liu, S.; Ren, Z.; Yu, Z. Dysbiosis in the Human Microbiome of Cholangiocarcinoma. Front. Physiol. 2021, 12, 715536. [Google Scholar] [CrossRef]
  34. Renzulli, M.; Brandi, N.; Pecorelli, A.; Pastore, L.V.; Granito, A.; Martinese, G.; Tovoli, F.; Simonetti, M.; Dajti, E.; Colecchia, A.; et al. Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers. Diagn. 2022, 12, 834. [Google Scholar] [CrossRef] [PubMed]
  35. Tripathi, A.; Debelius, J.; Brenner, D.A.; Karin, M.; Loomba, R.; Schnabl, B.; Knight, R. The gut-liver axis and the intersection with the microbiome. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 397–411. [Google Scholar] [CrossRef] [PubMed]
  36. Couto, N.; Al-Majdoub, Z.M.; Gibson, S.; Davies, P.J.; Achour, B.; Harwood, M.D.; Carlson, G.; Barber, J.; Rostami-Hodjegan, A.; Warhurst, G. Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small Intestine. Drug Metab. Dispos. 2020, 48, 245–254. [Google Scholar] [CrossRef] [PubMed]
  37. Yamazaki, K.; Kato, T.; Tsuboi, Y.; Miyauchi, E.; Suda, W.; Sato, K.; Nakajima, M.; Yokoji-Takeuchi, M.; Yamada-Hara, M.; Tsuzuno, T.; et al. Oral Pathobiont-Induced Changes in Gut Microbiota Aggravate the Pathology of Nonalcoholic Fatty Liver Disease in Mice. Front. Immunol. 2021, 12, 766170. [Google Scholar] [CrossRef] [PubMed]
  38. Tilg, H.; Cani, P.D.; Mayer, E.A. Gut microbiome and liver diseases. Gut 2016, 65, 2035–2044. [Google Scholar] [CrossRef]
  39. Brignardello, J.; Morales, P.; Diaz, E.; Romero, J.; Brunser, O.; Gotteland, M. Pilot study: Alterations of intestinal microbiota in obese humans are not associated with colonic inflammation or disturbances of barrier function. Aliment. Pharmacol. Ther. 2010, 32, 1307–1314. [Google Scholar] [CrossRef]
  40. Farhadi, A.; Gundlapalli, S.; Shaikh, M.; Frantzides, C.; Harrell, L.; Kwasny, M.M.; Keshavarzian, A. Susceptibility to gut leakiness: A possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int. 2008, 28, 1026–1033. [Google Scholar] [CrossRef]
  41. Acharya, C.; Sahingur, S.E.; Bajaj, J.S. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. J.CI Insight 2017, 2, e94416. [Google Scholar] [CrossRef] [PubMed]
  42. Qin, N.; Yang, F.; Li, A.; Prifti, E.; Chen, Y.; Shao, L.; Guo, J.; Le Chatelier, E.; Yao, J.; Wu, L.; et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014, 513, 59–64. [Google Scholar] [CrossRef] [PubMed]
  43. Kakiyama, G.; Hylemon, P.B.; Zhou, H.; Pandak, W.M.; Heuman, D.M.; Kang, D.J.; Takei, H.; Nittono, H.; Ridlon, J.M.; Fuchs, M.; et al. Colonic inflammation and secondary bile acids in alcoholic cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2014, 306, G929–G937. [Google Scholar] [CrossRef] [PubMed]
  44. Ahn, J.S.; Yang, J.W.; Oh, S.J.; Shin, Y.Y.; Kang, M.J.; Park, H.R.; Seo, Y.; Kim, H.S. Porphyromonas gingivalis exacerbates the progression of fatty liver disease via C.D36-P.PA.Rγ pathway. BMB Rep. 2021, 54, 323–328. [Google Scholar] [CrossRef] [PubMed]
  45. Fairfield, B.; Schnabl, B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep. 2020, 3, 100220. [Google Scholar] [CrossRef] [PubMed]
  46. Abe, K.; Takahashi, A.; Fujita, M.; Imaizumi, H.; Hayashi, M.; Okai, K.; Ohira, H. Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS ONE 2018, 13, e0198757. [Google Scholar] [CrossRef] [PubMed]
  47. Nagasaki, A.; Sakamoto, S.; Chea, C.; Ishida, E.; Furusho, H.; Fujii, M.; Takata, T.; Miyauchi, M. Odontogenic infection by Porphyromonas gingivalis exacerbates fibrosis in NASH via hepatic stellate cell activation. Sci. Rep. 2020, 10, 4134. [Google Scholar] [CrossRef] [PubMed]
  48. Jensen, A.; Ladegaard Grønkjær, L.; Holmstrup, P.; Vilstrup, H.; Kilian, M. Unique subgingival microbiota associated with periodontitis in cirrhosis patients. Sci. Rep. 2018, 8, 10718. [Google Scholar] [CrossRef]
  49. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J. Hepatol. 2018, 69, 154–181. [Google Scholar] [CrossRef]
  50. Roerecke, M.; Shield, K.D.; Higuchi, S.; Yoshimura, A.; Larsen, E.; Rehm, M.X.; Rehm, J. Estimates of alcohol-related oesophageal cancer burden in Japan: Systematic review and meta-analyses. Bull. World Health Organ. 2015, 93, 329–338C. [Google Scholar] [CrossRef]
  51. Li, F.; McClain, C.J.; Feng, W. Microbiome dysbiosis and alcoholic liver disease. Liver Res. 2019, 3, 218–226. [Google Scholar] [CrossRef] [PubMed]
  52. Fan, X.; Peters, B.A.; Jacobs, E.J.; Gapstur, S.M.; Purdue, M.P.; Freedman, N.D.; Alekseyenko, A.V.; Wu, J.; Yang, L.; Pei, Z.; et al. Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults. Microbiome 2018, 6, 59. [Google Scholar] [CrossRef] [PubMed]
  53. Zhou, Y.; Vatsalya, V.; Gobejishvili, L.; Lamont, R.J.; McClain, C.J.; Feng, W. Porphyromonas gingivalis as a Possible Risk Factor in the Development/Severity of Acute Alcoholic Hepatitis. Hepatol. Commun. 2018, 3, 293–304. [Google Scholar] [CrossRef] [PubMed]
  54. Sarin, S.K.; Pande, A.; Schnabl, B. Microbiome as a therapeutic target in alcohol-related liver disease. J. Hepatol. 2019, 70, 260–272. [Google Scholar] [CrossRef]
  55. Kuraji, R.; Shiba, T.; Dong, T.S.; Numabe, Y.; Kapila, Y.L. Periodontal treatment and microbiome-targeted therapy in management of periodonti-tis-related nonalcoholic fatty liver disease with oral and gut dysbiosis. World J. Gastroenterol. 2023, 29, 967–996. [Google Scholar] [CrossRef] [PubMed]
  56. Kamata, Y.; Kessoku, T.; Shimizu, T.; Kobayashi, T.; Kurihashi, T.; Sato, S.; Kuraji, S.; Aoyama, N.; Iwasaki, T.; Takashiba, S.; et al. Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: Protocol of the PERION multicenter, two-arm, open-label, randomized trial. Trials 2020, 21, 291. [Google Scholar] [CrossRef] [PubMed]
  57. Yoneda, M.; Naka, S.; Nakano, K.; Wada, K.; Endo, H.; Mawatari, H.; Imajo, K.; Nomura, R.; Hokamura, K.; Ono, M.; et al. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Gastroenterol. 2012, 12, 16. [Google Scholar] [CrossRef]
  58. Nagasaki, A.; Sakamoto, S.; Arai, T.; Kato, M.; Ishida, E.; Furusho, H.; Fujii, M.; Takata, T.; Miyauchi, M. Elimination of Porphyromonas gingivalis inhibits liver fibrosis and inflammation in NASH. J. Clin. Periodontol. 2021, 48, 1367–1378. [Google Scholar] [CrossRef]
  59. Yao, C.; Lan, D.; Li, X.; Wang, Y.; Qi, S.; Liu, Y. Porphyromonas gingivalis is a risk factor for the development of nonalcoholic fatty liver disease via ferroptosis. Microbes Infect. 2023, 25, 105040. [Google Scholar] [CrossRef]
  60. Seyama, M.; Yoshida, K.; Yoshida, K.; Fujiwara, N.; Ono, K.; Eguchi, T.; Kawai, H.; Guo, J.; Weng, Y.; Haoze, Y. Outer membrane vesicles of Porphyromonas gingivalis attenuate insulin sensitivity by delivering gingipains to the liver. Biochim. Biophys. Acta Mol. Basis Dis. 2020, 1866, 165731. [Google Scholar] [CrossRef]
  61. Seen, S. Chronic liver disease and oxidative stress—A narrative review. Expert. Rev. Gastroenterol. Hepatol. 2021, 15, 1021–1035. [Google Scholar] [CrossRef] [PubMed]
  62. Bajaj, J.S.; Matin, P.; White, M.B.; Fagan, A.; Deeb, J.G.; Acharya, C.; Dalmet, S.S.; Sikaroodi, M.; Gillevet, P.M.; Sahingur, S.E. Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2018, 315, G824–G837. [Google Scholar] [CrossRef] [PubMed]
  63. Costa, F.O.; Lages, E.J.P.; Lages, E.M.B.; Cota, L.O.M. Periodontitis in individuals with liver cirrhosis: A case-control study. J. Clin. Periodontol. 2019, 46, 991–998. [Google Scholar] [CrossRef] [PubMed]
  64. Ladegaard Grønkjær, L.; Holmstrup, P.; Schou, S.; Jepsen, P.; Vilstrup, H. Severe periodontitis and higher cirrhosis mortality. United Eur. Gastroenterol. J. 2018, 6, 73–80. [Google Scholar] [CrossRef] [PubMed]
  65. Di Profio, B.; Villar, C.C.; Saraiva, L.; Ortega, K.L.; Pannuti, C.M. Is periodontitis a risk factor for infections in cirrhotic patients? Med. Hypotheses 2017, 106, 19–22. [Google Scholar] [CrossRef] [PubMed]
  66. Omura, Y.; Kitamoto, M.; Hyogo, H.; Yamanoue, T.; Tada, Y.; Boku, N.; Nishisaka, T.; Miyauchi, M.; Takata, T.; Chayama, K. Morbidly obese patient with non-alcoholic steatohepatitis-related cirrhosis who died from sepsis caused by dental infection of Porphyromonas gingivalis: A case report. Hepatol. Res. 2016, 46, E210–E215. [Google Scholar] [CrossRef] [PubMed]
  67. Hernandez, B.Y.; Zhu, X.; Risch, H.A.; Lu, L.; Ma, X.; Irwin, M.L.; Lim, J.K.; Taddei, T.H.; Pawlish, K.S.; Stroup, A.M. Oral Cyanobacteria and Hepatocellular Carcinoma. Cancer Epidemiol. Biomark. Prev. 2022, 31, 221–229. [Google Scholar] [CrossRef]
  68. Thistle, J.E.; Yang, B.; Petrick, J.L.; Fan, J.H.; Qiao, Y.L.; Abnet, C.C.; Taylor, P.R.; McGlynn, K.A. Association of tooth loss with liver cancer incidence and chronic liver disease mortality in a rural Chinese population. PLoS ONE 2018, 13, e0203926. [Google Scholar] [CrossRef]
  69. Yang, B.; Petrick, J.L.; Abnet, C.C.; Graubard, B.I.; Murphy, G.; Weinstein, S.J.; Männistö, S.; Albanes, D.; McGlynn, K.A. Tooth loss and liver cancer incidence in a Finnish cohort. Cancer Causes Control. 2017, 28, 899–904. [Google Scholar] [CrossRef]
  70. Schwabe, R.F.; Greten, T.F. Gut microbiome in H.CC—Mechanisms, diagnosis and therapy. J. Hepatol. 2020, 72, 230–238. [Google Scholar] [CrossRef]
  71. Hedgpeth, D.C.; Zhang, X.; Jin, J.; Leite, R.S.; Krayer, J.W.; Huang, Y. Periodontal, C.D14 mR.NA expression is downregulated in patients with chronic periodontitis and type 2 diabetes. BMC Oral. Health 2015, 15, 145. [Google Scholar] [CrossRef] [PubMed]
  72. Wu, J.S.; Zheng, M.; Zhang, M.; Pang, X.; Li, L.; Wang, S.S.; Yang, X.; Wu, J.B.; Tang, Y.J.; Tang, Y.L.; et al. Porphyromonas gingivalis Promotes 4-Nitroquinoline-1-Oxide-Induced Oral Carcinogenesis with an Alteration of Fatty Acid Metabolism. Front. Microbiol. 2018, 9, 2081. [Google Scholar] [CrossRef] [PubMed]
  73. Lin, Y.W.; Li, C.F.; Chen, H.Y.; Yen, C.Y.; Lin, L.C.; Huang, C.C.; Huang, H.Y.; Wu, P.C.; Chen, C.H.; Chen, S.C.; et al. The expression and prognostic significance of hepatoma-derived growth factor in oral cancer. Oral. Oncol. 2012, 48, 629–635. [Google Scholar] [CrossRef] [PubMed]
  74. Rao, B.C.; Lou, J.M.; Wang, W.J.; Li, A.; Cui, G.Y.; Yu, Z.J.; Ren, Z.G. Human microbiome is a diagnostic biomarker in hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 2020, 19, 109–115. [Google Scholar] [CrossRef] [PubMed]
  75. du Teil Espina, M.; Gabarrini, G.; Harmsen, H.J.M.; Westra, J.; van Winkelhoff, A.J.; van Dijl, J.M. Talk to your gut: The oral-gut microbiome axis and its immunomodulatory role in the etiology of rheumatoid arthritis. FEMS Microbiol. Rev. 2019, 43, 1–18. [Google Scholar] [CrossRef] [PubMed]
  76. Tanaka, A.; Leung, P.S.C.; Gershwin, M.E. Pathogen infections and primary biliary cholangitis. Clin. Exp. Immunol. 2019, 195, 25–34. [Google Scholar] [CrossRef] [PubMed]
  77. Shimoda, S.; Nakamura, M.; Ishibashi, H.; Hayashida, K.; Niho, Y.H.L.A. D.RB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: Evidence of molecular mimicry in human autoimmune diseases. J. Exp. Med. 1995, 181, 1835–1845. [Google Scholar] [CrossRef]
  78. Rao, B.; Lou, J.; Lu, H.; Liang, H.; Li, J.; Zhou, H.; Fan, Y.; Zhang, H.; Sun, Y.; Zou, Y.; et al. Oral Microbiome Characteristics in Patients With Autoimmune Hepatitis. Front. Cell Infect. Microbiol. 2021, 11, 656674. [Google Scholar] [CrossRef]
  79. Han, Y.W. Fusobacterium nucleatum: A commensal-turned pathogen. Curr. Opin. Microbiol. 2015, 23, 141–147. [Google Scholar] [CrossRef]
  80. Durand, R.; Roufegarinejad, A.; Chandad, F.; Rompré, P.H.; Voyer, R.; Michalowicz, B.S.; Emami, E. Dental caries are positively associated with periodontal disease severity. Clin. Oral. Investig. 2019, 23, 3811–3819. [Google Scholar] [CrossRef]
  81. Kilian, M. The oral microbiome—Friend or foe? Eur. J. Oral. Sci. 2018, 126 (Suppl. S1), 5–12. [Google Scholar] [CrossRef]
  82. Sälzer, S.; Graetz, C.; Dörfer, C.E.; Slot, D.E.; Van der Weijden, F.A. Contemporary practices for mechanical oral hygiene to prevent periodontal disease. Periodontol. 2000 2020, 84, 35–44. [Google Scholar] [CrossRef]
  83. Chapple, I.L.; Van der Weijden, F.; Doerfer, C.; Herrera, D.; Shapira, L.; Polak, D.; Madianos, P.; Louropoulou, A.; Machtei, E.; Donos, N.; et al. Primary prevention of periodontitis: Managing gingivitis. J. Clin. Periodontol. 2015, 42 (Suppl. 16), S71–S76. [Google Scholar] [CrossRef] [PubMed]
  84. Kim, J.Y.; Park, Y.M.; Lee, G.N.; Song, H.C.; Ahn, Y.B.; Han, K.; Ko, S.H. Association between toothbrushing and non-alcoholic fatty liver disease. PLoS ONE 2021, 16, e0243686. [Google Scholar] [CrossRef] [PubMed]
  85. Kamata, Y.; Kessoku, T.; Shimizu, T.; Sato, S.; Kobayashi, T.; Kurihashi, T.; Morozumi, T.; Iwasaki, T.; Takashiba, S.; Hatanaka, K.; et al. Periodontal Treatment and Usual Care for Nonalcoholic Fatty Liver Disease: A Multicenter, Randomized Controlled Trial. Clin. Transl. Gastroenterol. 2022, 13, e00520. [Google Scholar] [CrossRef] [PubMed]
  86. Niu, J.Y.; Yin, I.X.; Mei, M.L.; Wu, W.K.K.; Li, Q.L.; Chu, C.H. The multifaceted roles of antimicrobial peptides in oral diseases. Mol. Oral. Microbiol. 2021, 36, 159–171. [Google Scholar] [CrossRef] [PubMed]
  87. Signat, B.; Roques, C.; Poulet, P.; Duffaut, D. Fusobacterium nucleatum in periodontal health and disease. Curr. Issues Mol. Biol. 2011, 13, 25–36. [Google Scholar] [PubMed]
  88. Tonelli, A.; Lumngwena, E.N.; Ntusi, N.A.B. The oral microbiome in the pathophysiology of cardiovascular disease. Nat. Rev. Cardiol. 2023, 20, 386–403. [Google Scholar] [CrossRef] [PubMed]
  89. Pütsep, K.; Carlsson, G.; Boman, H.G.; Andersson, M. Deficiency of antibacterial peptides in patients with morbus Kostmann: An observation study. Lancet 2002, 360, 1144–1149. [Google Scholar] [CrossRef]
  90. Gäbele, E.; Dostert, K.; Hofmann, C.; Wiest, R.; Schölmerich, J.; Hellerbrand, C.; Obermeier, F. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in ex-perimental NASH. J. Hepatol. 2011, 55, 1391–1399. [Google Scholar] [CrossRef]
  91. Wang, Q.; Kim, S.Y.; Matsushita, H.W.; Wang, Z.; Pandyarajan, V.; Matsuda, M.; Ohashi, K.; Tsuchiya, T.; Roh, Y.S.; Kiani, C.; et al. Oral administration of P.EGylated, T.LR7 ligand ameliorates alcohol-associated liver disease via the induction of I.L-22. Proc. Natl. Acad. Sci. USA 2021, 118, e2020868118. [Google Scholar]
  92. Ding, X.; Bian, D.; Li, W.; Xie, Y.; Li, X.; Lv, J.; Tang, R. Host defense peptide L.L-37 is involved in the regulation of cell proliferation and production of pro-inflammatory cytokines in hepatocellular carcinoma cells. Amino Acids 2021, 53, 471–484. [Google Scholar] [CrossRef] [PubMed]
  93. Sanders, M.E.; Merenstein, D.J.; Reid, G.; Gibson, G.R.; Rastall, R.A. Probiotics and prebiotics in intestinal health and disease: From biology to the clinic. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 605–616. [Google Scholar] [CrossRef] [PubMed]
  94. Maitre, Y.; Mahalli, R.; Micheneau, P.; Delpierre, A.; Guerin, M.; Amador, G.; Denis, F. Pre and Probiotics Involved in the Modulation of Oral Bacterial Species: New Therapeutic Leads in Mental Disorders? Microorganisms 2021, 9, 1450. [Google Scholar] [CrossRef] [PubMed]
  95. Bashiardes, S.; Shapiro, H.; Rozin, S.; Shibolet, O.; Elinav, E. Non-alcoholic fatty liver and the gut microbiota. Mol. Metab. 2016, 5, 782–794. [Google Scholar] [CrossRef]
  96. Aron-Wisnewsky, J.; Warmbrunn, M.V.; Nieuwdorp, M.; Clément, K. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Gastroenterology 2020, 158, 1881–1898. [Google Scholar] [CrossRef] [PubMed]
  97. Matsubara, V.H.; Bandara, H.M.; Ishikawa, K.H.; Mayer, M.P.; Samaranayake, L.P. The role of probiotic bacteria in managing periodontal disease: A systematic review. Expert. Rev. Anti. Infect. Ther. 2016, 14, 643–655. [Google Scholar] [CrossRef]
  98. Sharpton, S.R.; Maraj, B.; Harding-Theobald, E.; Vittinghoff, E.; Terrault, N.A. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: A systematic review, meta-analysis, and meta-regression. Am. J. Clin. Nutr. 2019, 110, 139–149. [Google Scholar] [CrossRef]
  99. Ahn, S.B.; Jun, D.W.; Kang, B.K.; Lim, J.H.; Lim, S.; Chung, M.J. Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease. Sci. Rep. 2019, 9, 5688. [Google Scholar] [CrossRef]
  100. Zhao, X.; Liu, J.; Zhang, C.; Yu, N.; Lu, Z.; Zhang, S.; Li, Y.; Li, Q.; Liu, J.; Liu, D.; et al. Porphyromonas gingivalis exacerbates ulcerative colitis via Porphyromonas gingivalis peptidylarginine deiminase. Int. J. Oral. Sci. 2021, 13, 31. [Google Scholar] [CrossRef]
  101. Bregaint, S.; Boyer, E.; Fong, S.B.; Meuric, V.; Bonnaure-Mallet, M.; Jolivet-Gougeon, A. Porphyromonas gingivalis outside the oral cavity. Odontology 2022, 110, 1–19. [Google Scholar] [CrossRef] [PubMed]
  102. Ding, L.Y.; Liang, L.Z.; Zhao, Y.X.; Yang, Y.N.; Liu, F.; Ding, Q.R.; Luo, L.J. Porphyromonas gingivalis-derived lipopolysaccharide causes excessive hepatic lipid accumulation via activating N.F-κB and J.NK signaling pathways. Oral. Dis. 2019, 25, 1789–1797. [Google Scholar] [CrossRef] [PubMed]
  103. Olsen, I.; Yilmaz, Ö. Possible role of Porphyromonas gingivalis in orodigestive cancers. J. Oral. Microbiol. 2019, 11, 1563410. [Google Scholar] [CrossRef] [PubMed]
  104. Liu, Y.; Huang, W.; Dai, K.; Liu, N.; Wang, J.; Lu, X.; Ma, J.; Zhang, M.; Xu, M.; Long, X.; et al. Inflammatory response of gut, spleen, and liver in mice induced by orally administered Porphyromonas gingivalis. J. Oral. Microbiol. 2022, 14, 2088936. [Google Scholar] [CrossRef] [PubMed]
  105. Mohammed, H.; Varoni, E.M.; Cochis, A.; Cordaro, M.; Gallenzi, P.; Patini, R.; Staderini, E.; Lajolo, C.; Rimondini, L.; Rocchetti, V. Oral Dysbiosis in Pancreatic Cancer and Liver Cirrhosis: A Review of the Literature. Biomedicines. 2018, 6, 115. [Google Scholar] [CrossRef] [PubMed]
  106. Ohyama, H.; Nakasho, K.; Yamanegi, K.; Noiri, Y.; Kuhara, A.; Kato-Kogoe, N.; Yamada, N.; Hata, M.; Nishimura, F.; Ebisu, S.; et al. An unusual autopsy case of pyogenic liver abscess caused by periodontal bacteria. Jpn. J. Infect. Dis. 2009, 62, 381–383. [Google Scholar] [CrossRef] [PubMed]
  107. Brock, M.; Bahammam, S.; Sima, C. The Relationships Among Periodontitis, Pneumonia and COVID-19. Front. Oral. Health 2022, 2, 801815. [Google Scholar] [CrossRef] [PubMed]
  108. Pone, E.J.; Zan, H.; Zhang, J.; Al-Qahtani, A.; Xu, Z.; Casali, P. Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch D.NA recombination: Relevance to microbial antibody responses. Crit. Rev. Immunol. 2010, 30, 1–29. [Google Scholar] [CrossRef]
  109. Han, P.; Sun, D.; Yang, J. Interaction between periodontitis and liver diseases. Biomed. Rep. 2016, 5, 267–276. [Google Scholar] [CrossRef]
  110. Barcelos, R.C.S.; Rosa, H.Z.; Roversi, K.; Tibúrcio-Machado, C.D.S.; Inchaki, P.T.; Burger, M.E.; Bier, C.A.S. Apical periodontitis induces changes on oxidative stress parameters and increases Na+/K+-A.TPase activity in adult rats. Arch. Oral. Biol. 2020, 118, 104849. [Google Scholar] [CrossRef]
  111. Chen, H.T.; Huang, H.L.; Li, Y.Q.; Xu, H.M.; Zhou, Y.J. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view. World J. Gastroenterol. 2020, 26, 1901–1911. [Google Scholar] [CrossRef]
  112. Boursier, J.; Mueller, O.; Barret, M.; Machado, M.; Fizanne, L.; Araujo-Perez, F.; Guy, C.D.; Seed, P.C.; Rawls, J.F.; David, L.A. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016, 63, 764–775. [Google Scholar] [CrossRef] [PubMed]
  113. Baker, J.L.; Mark Welch, J.L.; Kauffman, K.M.; McLean, J.S.; He, X. The oral microbiome: Diversity, biogeography and human health. Nat. Rev. Microbiol. 2023, 1–16. [Google Scholar] [CrossRef] [PubMed]
  114. Sookoian, S.; Salatino, A.; Castaño, G.O.; Landa, M.S.; Fijalkowky, C.; Garaycoechea, M.; Pirola, C.J. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut 2020, 69, 1483–1491. [Google Scholar] [CrossRef] [PubMed]
  115. Van Pijkeren, J.P.; Neoh, K.M.; Sirias, D.; Findley, A.S.; Britton, R.A. Exploring optimization parameters to increase ssD.NA recombineering in Lactococcus lactis and Lactobacillus reuteri. Bioengineered 2012, 3, 209–217. [Google Scholar] [CrossRef] [PubMed]
  116. Tawfik, S.A.; Azab, M.; Ramadan, M.; Shabayek, S.; Abdellah, A.; Al Thagfan, S.S.; Salah, M. The Eradication of Helicobacter pylori Was Significantly Associated with Compositional Patterns of Orointestinal Axis Microbiota. Pathogens 2023, 12, 832. [Google Scholar] [CrossRef]
Diagnostics 13 03324 g001
Figure 1. Oral pathogenic bacteria can disseminate by different routes—haematogenous or gastrointestinal—to reach the liver, where they can cause or exacerbate inflammatory pathologies. When periodontitis occurs, oral pathogenic bacteria can enter the blood circulation through the damaged oral mucosa, thereby reaching the liver. Alternatively, oral pathogenic bacteria may enter the gastrointestinal circulation by swallowing saliva, causing intestinal biological disorders and intestinal barrier function damage, thus contributing to endotoxemia and inflammation. Then, due to the presence of enterohepatic circulation, these effects may directly trigger or exacerbate pre-existing liver damage through detrimental metabolic consequences, resulting in liver steatosis, chronic hepatitis, fibrosis, and cirrhosis, and the progression of cirrhosis to hepatocellular carcinoma.
Figure 1. Oral pathogenic bacteria can disseminate by different routes—haematogenous or gastrointestinal—to reach the liver, where they can cause or exacerbate inflammatory pathologies. When periodontitis occurs, oral pathogenic bacteria can enter the blood circulation through the damaged oral mucosa, thereby reaching the liver. Alternatively, oral pathogenic bacteria may enter the gastrointestinal circulation by swallowing saliva, causing intestinal biological disorders and intestinal barrier function damage, thus contributing to endotoxemia and inflammation. Then, due to the presence of enterohepatic circulation, these effects may directly trigger or exacerbate pre-existing liver damage through detrimental metabolic consequences, resulting in liver steatosis, chronic hepatitis, fibrosis, and cirrhosis, and the progression of cirrhosis to hepatocellular carcinoma.
Diagnostics 13 03324 g001
Table 1. Characteristics of main oral pathogenic bacteria.
Table 1. Characteristics of main oral pathogenic bacteria.
SpeciesP. gingivalisS. mutansP. intermediaA. actinomycetemcomitansF. nucleatum
PhylumBacteroidetesFirmicutesBacteroidetesProteobacteriaFusobacteria
Gram stainNegativePostivePostiveNegativeNegative
Respiration characteristicAnaerobicFacultative anaerobeAnaerobicFacultative anaerobeAnaerobic
Main locationGingivaPlaqueGingivaGingivaPlaque
Table 2. Changes in the oral microbiota related to liver diseases.
Table 2. Changes in the oral microbiota related to liver diseases.
Type of Liver DiseasesMicrobial Genus of Potential Diagnostic Biomarkers ReferencesClinical Significance
ALDP. gingivalis↑[44]P. gingivalis may be a risk factor for the occurrence/severity of AAH.
Fusobacterium↑
Veillonella↑
Bifidobacterium↑
Lactobacillus ↑
Streptococcus ↑		[45]Patients with alcohol-associated cirrhosis and alcoholic hepatitis are enriched for more common pathogenic taxa.
AILDAIHStreptococcus↑
Veillonella ↑
Leptotrichia↑		[33]Oral microbiota-targeted biomarkers may be able to serve as powerful and noninvasive diagnostic tools for AIH.
AIHVeillonella↑
Streptococcus↓		[46]Further studies of the establishment and modification of the oral microbiota structure may contribute to the development of a therapeutic strategy for patients with AILD.
PBCEubacterium↑
Veillonella↑
Fusobacterium↓
NAFLDP. gingivalis↑[47]P. gingivalis induced the activation of hepatic stellate cells (HSCs; key effector cells in liver fibrosis).
P. gingivalis ↑[44]P. gingivalis can induce the progression of fatty liver disease in HFD-fed mice through the upregulation of the CD36-PPARγ axis.
CirrhosisBacteroidetes↑
Spirochaetes↑
Fusobacteria↑
Tannerella forsythia↓
Treponema denticala↓		[48]The subgingival plaque microbiome in patients with liver cirrhosis and periodontitis differed from that of otherwise healthy patients with periodontitis.
HCCGammaproteobacteria ↓
Bacteroidetes↓
Epsilonproteobacteria↑
Actinobacteria↑
Clostridia↑
Fusobacteria↑		[31]The oral microbiome serves as a diagnostic biomarker for HCC.
Upward arrows indicate increasing abundance, downward arrows indicate decreasing abundance.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lei, Y.; Li, S.; He, M.; Ao, Z.; Wang, J.; Wu, Q.; Wang, Q. Oral Pathogenic Bacteria and the Oral–Gut–Liver Axis: A New Understanding of Chronic Liver Diseases. Diagnostics 2023, 13, 3324. https://doi.org/10.3390/diagnostics13213324

AMA Style

Lei Y, Li S, He M, Ao Z, Wang J, Wu Q, Wang Q. Oral Pathogenic Bacteria and the Oral–Gut–Liver Axis: A New Understanding of Chronic Liver Diseases. Diagnostics. 2023; 13(21):3324. https://doi.org/10.3390/diagnostics13213324

Chicago/Turabian Style

Lei, Yumeng, Simin Li, Mingxin He, Zichun Ao, Jiadun Wang, Qingming Wu, and Qiang Wang. 2023. "Oral Pathogenic Bacteria and the Oral–Gut–Liver Axis: A New Understanding of Chronic Liver Diseases" Diagnostics 13, no. 21: 3324. https://doi.org/10.3390/diagnostics13213324

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop